Generics - Biotechnology, Global


Current filters:


Popular Filters

Global biosimilar drug revenues will reach $2,445 million in 2013, says Visiongain


The world market for biosimilar drugs will be worth $2,445 million in 2013, growing by more than 20%…

BiotechnologyCellTrionGenericsGlobalHospiraMarkets & MarketingSandoz

Pfenex and Agila Biotech set up JV to develop biosimilars


US biotech firm Pfenex Inc. and Agila Biotech, a subsidiary of Indian drugmaker Strides Arcolab (BO:…

Agila BiotechBayerBetaferonBetaseronBiotechnologyGenericsGlobalNeurologicalPfenexProductionResearchStrides Arcolab

Support for introduction of a global regulatory process for biosimilars


The majority of surveyed US and European physicians and payers are in favor of the introduction of a…


Sales of antiretroviral agents for HIV will decline slightly over next decade


Major-market sales of antiretroviral (ARV) agents for HIV will decline slightly over the next decade,…

Anti-viralsBiotechnologydolutegravirGenericsGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRegulationViiV Healthcare

Big Pharma embraces biologics


Fast-evolving biopharmaceuticals will challenge synthetic market dominance in the global market for active…

BiotechnologyGenericsGlobalMarkets & Marketing

Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021


Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Biosimilar versions of MAbs for cancer forecast to garner sales of $4.9 billion in 2021


While branded versions of monoclonal antibodies for cancer are expected to maintain sales of $6.7 million…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

"Sandoz will be the leading biosimilars company in 2012," says Visiongain


Sandoz, the generics unit of Swiss drug major Novartis (NVN: VX), will retain its position as the global…

BiotechnologyDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingNovartisSandoz

World awaits "Biosimilars Boom," says GBI Research


With an introduction to the USA set for 2014, and the realization of massive potential in the emerging…

BiotechnologyGenericsGlobalMarkets & Marketing

Uptake of biosimilars will see Remicade and Humira sales decline in 2017


The TNF-alpha inhibitors infliximab (Janssen Biotech/Merck/Mitsubishi Tanabe's Remicade) and adalimumab…

BiotechnologyGastro-intestinalsGenericsGlobalHumiraMarkets & MarketingRemicade

World's first (official) biosimilar antibody goes to reumatoid arthritis


The end of July 2012 proved exciting for the world of biosimilar manufacturers. However, for the regulatory…

BiotechnologyCellTrionGenericsGlobalinfliximabJohnson & JohnsonMarkets & MarketingRegulationRemicadeRemsima

Pharma industry calls for broad-based cooperation to fight on-line sales of counterfeit medicines


The global pharmaceutical industry unveiled recommendations this week to tackle the growing public health…

BiotechnologyGenericsGlobalMarkets & MarketingPharmaceuticalRegulation

Global medicines spending set to rebound, reaching nearly $1.2 trillion by 2016, says IMS


Following several years of slowing growth, the global market for medicines is poised to rebound from…

BiotechnologyGenericsGlobalHealthcareMarkets & MarketingPatentsPharmaceutical

Crucial need for global development of biosimilars, says head of European generics group


"The need for a framework which allows global biosimilars development is now crucial," argued European…


Likelihood of big uptake of biosimilars by 2020 questioned


The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this…

BiotechnologyGenericsGlobalMarkets & MarketingPatentsRegulation

Amgen in cancer biosimilars deal with Watson


A collaboration has been entered into by Amgen (Nasdaq: AMGN), the world’s largest independent biotech…

AmgenBiotechnologyGenericsGlobalLicensingMarkets & MarketingOncologyWatson Pharmaceuticals

Some 40% of G7 ESA markets to be biosimilars by 2020, and insulins to reach $1 billion, says DR report


By 2020, biosimilar versions of erythropoietin stimulating agents (ESAs) will garner 40% market share…

BiotechnologyDiabetesGenericsGlobalMarkets & MarketingOncology

Back to top